IL215584A - Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system - Google Patents
Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous systemInfo
- Publication number
- IL215584A IL215584A IL215584A IL21558411A IL215584A IL 215584 A IL215584 A IL 215584A IL 215584 A IL215584 A IL 215584A IL 21558411 A IL21558411 A IL 21558411A IL 215584 A IL215584 A IL 215584A
- Authority
- IL
- Israel
- Prior art keywords
- piperidine
- diol
- fluoromethyl
- chloromethyl
- medicament
- Prior art date
Links
- KTXBXDGOZMHNIC-UHFFFAOYSA-N 5-(chloromethyl)piperidine-3,4-diol Chemical compound OC1CNCC(CCl)C1O KTXBXDGOZMHNIC-UHFFFAOYSA-N 0.000 title 1
- BEQPGACEJJJLEA-UHFFFAOYSA-N 5-(fluoromethyl)piperidine-3,4-diol Chemical compound OC1CNCC(CF)C1O BEQPGACEJJJLEA-UHFFFAOYSA-N 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16810109P | 2009-04-09 | 2009-04-09 | |
| PCT/US2010/030470 WO2010118282A1 (en) | 2009-04-09 | 2010-04-09 | Methods for preventing and/or treating degenerative disorders of the central nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL215584A0 IL215584A0 (en) | 2011-12-29 |
| IL215584A true IL215584A (en) | 2016-11-30 |
Family
ID=42934882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215584A IL215584A (en) | 2009-04-09 | 2011-10-06 | Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8304429B2 (https=) |
| EP (1) | EP2416655B1 (https=) |
| JP (1) | JP5634498B2 (https=) |
| CN (1) | CN102448306B (https=) |
| AU (1) | AU2010233187B2 (https=) |
| BR (1) | BRPI1015472A2 (https=) |
| CA (1) | CA2758187C (https=) |
| ES (1) | ES2505243T3 (https=) |
| IL (1) | IL215584A (https=) |
| NZ (1) | NZ595630A (https=) |
| WO (1) | WO2010118282A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8940766B2 (en) * | 2009-04-09 | 2015-01-27 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
| WO2011049737A1 (en) * | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| SI2490532T1 (sl) | 2009-10-19 | 2017-03-31 | Amicus Therapeutics, Inc. | Novi sestavki za preventivo in/ali zdravljenje degenerativnih motenj centralnega živčnega sistema |
| CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
| WO2013070981A2 (en) * | 2011-11-08 | 2013-05-16 | University Of Central Florida Research Foundation, Inc. | Treating er stress related disorders by stabilizing intracellular calcium homeostasis |
| US9155695B2 (en) | 2013-03-14 | 2015-10-13 | Medtronic, Inc. | Injectable ropinirole compositions and methods for making and using same |
| WO2015095963A1 (en) | 2013-12-23 | 2015-07-02 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| US10300155B2 (en) | 2015-12-31 | 2019-05-28 | Washington University | Alpha-synuclein ligands |
| CN110177572A (zh) * | 2016-09-12 | 2019-08-27 | 史蒂文·霍夫曼 | 用于治疗痴呆的组合物 |
| AR110074A1 (es) * | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
| BR112020013994A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos |
| EA202091693A1 (ru) | 2018-01-12 | 2021-04-14 | Бристол-Маерс Сквибб Компани | Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения |
| CN119606967B (zh) * | 2024-12-13 | 2025-09-05 | 合肥工业大学 | 氯雷他定在制备用于预防和治疗血管钙化药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995024391A1 (en) * | 1994-03-09 | 1995-09-14 | Novo Nordisk A/S | Piperidines and pyrrolidines |
| US20060079533A1 (en) * | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US6670625B1 (en) * | 2002-06-18 | 2003-12-30 | Ge Medical Systems Global Technology Company, Llc | Method and apparatus for correcting multipole aberrations of an electron beam in an EBT scanner |
| JP2006507359A (ja) * | 2002-10-28 | 2006-03-02 | ノボ・ノルデイスク・エー／エス | 心循環器疾患の治療のためのグリコーゲンホスホリラーゼ阻害剤の使用 |
| CN101541172A (zh) * | 2005-06-08 | 2009-09-23 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| JP5303458B2 (ja) * | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| US20080009156A1 (en) | 2006-07-10 | 2008-01-10 | Malin Glen K | System and method for bonding coaxial cable |
| US8940766B2 (en) * | 2009-04-09 | 2015-01-27 | Amicus Therapeutics, Inc. | Methods for preventing and/or treating lysosomal storage disorders |
-
2010
- 2010-04-09 CA CA2758187A patent/CA2758187C/en not_active Expired - Fee Related
- 2010-04-09 NZ NZ595630A patent/NZ595630A/xx not_active IP Right Cessation
- 2010-04-09 AU AU2010233187A patent/AU2010233187B2/en not_active Ceased
- 2010-04-09 JP JP2012504880A patent/JP5634498B2/ja active Active
- 2010-04-09 CN CN201080024142.1A patent/CN102448306B/zh not_active Expired - Fee Related
- 2010-04-09 WO PCT/US2010/030470 patent/WO2010118282A1/en not_active Ceased
- 2010-04-09 US US12/757,144 patent/US8304429B2/en not_active Expired - Fee Related
- 2010-04-09 BR BRPI1015472A patent/BRPI1015472A2/pt not_active Application Discontinuation
- 2010-04-09 EP EP10762468.6A patent/EP2416655B1/en active Active
- 2010-04-09 ES ES10762468.6T patent/ES2505243T3/es active Active
-
2011
- 2011-10-06 IL IL215584A patent/IL215584A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2505243T3 (es) | 2014-10-09 |
| US20100261753A1 (en) | 2010-10-14 |
| CN102448306B (zh) | 2014-07-02 |
| AU2010233187B2 (en) | 2015-10-08 |
| JP5634498B2 (ja) | 2014-12-03 |
| EP2416655B1 (en) | 2014-06-25 |
| CA2758187C (en) | 2017-03-07 |
| US8304429B2 (en) | 2012-11-06 |
| EP2416655A1 (en) | 2012-02-15 |
| CN102448306A (zh) | 2012-05-09 |
| BRPI1015472A2 (pt) | 2015-11-24 |
| HK1168005A1 (zh) | 2012-12-21 |
| CA2758187A1 (en) | 2010-10-14 |
| WO2010118282A1 (en) | 2010-10-14 |
| AU2010233187A1 (en) | 2011-11-03 |
| EP2416655A4 (en) | 2012-09-05 |
| IL215584A0 (en) | 2011-12-29 |
| JP2012523430A (ja) | 2012-10-04 |
| NZ595630A (en) | 2013-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215584A (en) | Use of 5- (fluoromethyl) piperidine-3,4-diol, 5- (chloromethyl) piperidine-3,4-diol for the preparation of a drug for the prevention and / or treatment of degenerative diseases of the central nervous system | |
| IL208390A0 (en) | Permeant delivery system and methods for use thereof | |
| PL2379132T3 (pl) | Układ i sposób infuzji leku | |
| EP2451367A4 (en) | DEVICES, SYSTEMS AND METHODS OF SKIN TREATMENT USED BY TIME-CONTROLLED RELEASED SUBSTANCES | |
| IL219107A0 (en) | 2-amino--5,5-difluoro-5,6-dihydro-4h-oxazines as bace 1 and/or bace 2 inhibitors | |
| EP2533747B8 (de) | Vorrichtung zur behandlung eines patienten mit vibrations-, tast- und/oder thermoreizen | |
| EP2115651A4 (en) | SYSTEMS AND METHODS FOR ONLINE GAMES | |
| IL225597A0 (en) | Pharmaceutical preparation, methods of treatment and its uses | |
| EP2491524A4 (en) | SYSTEM AND DEVICE FOR CONSOLIDATING SIM, PERSONAL TOKEN AND ASSOCIATED APPLICATIONS | |
| Vu et al. | Nonlinear electro-and magneto-elastostatics: material and spatial settings | |
| IL208336A (en) | Pyridazinone derivatives, drugs containing them and their uses and process for preparation | |
| IL220060A (en) | Diphenyl-pyrazolopyridine derivatives, their preparation and use as modulators for the nuclear receptor | |
| PL2401263T3 (pl) | Podstawione pochodne azotu, zawierająca pochodne kompozycja farmaceutyczna, i sposób leczenia choroby Parkinsona przy ich użyciu | |
| IL215583A (en) | Use of Medical Material 5- (Fluorine and Methyl) Pipridine-3,4-Diol, 5- (Chloromethyl) Pipridine-3,4-Diol for the preparation of a drug for the prevention and / or treatment of lysosomal storage disorders in patients at risk of disease or being diagnosed with these disorders | |
| EP2450038A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETIC NEUROPATHY AND MANUFACTURING AND USE METHODS | |
| EP2413837A4 (en) | METHODS FOR TREATING MYOFASCIAL, MUSCLE AND / OR BACK PAIN | |
| EP2127665A4 (en) | MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES | |
| IL182361A0 (en) | Play system for children, including playmat and playpieces | |
| IL214560A0 (en) | Durable treatment with 4-aminopyridine in patients with demyelination | |
| EP2266619A4 (de) | Pharmazeutische zusammensetzung auf basis eines leberschützenden mittels und eines präbiotischen mittels, ihre herstellung und verwendung | |
| ZA201201146B (en) | Isocyanate-terminated prepolymer,the method for preparing the same and the use thereof | |
| ZA201201011B (en) | Process for preparing levosimendan and intermediates for use in the process | |
| EP2005964A4 (en) | MEDICAMENT FOR TREATING HYPERPHOSPHATEEMIA AND PREPARATION METHOD THEREOF | |
| GB0821501D0 (en) | Method, composition, and device, for the treatment of enzymes and saccharides disorder | |
| EP2106604A4 (en) | IMPROVED OPTIONAL DEVICE AND SYSTEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |